The final draft version of new, updated, and revised BNF Publications content is periodically displayed on this page for open review.
This draft content has been validated against emerging evidence, best-practice guidelines, and advice from a network of clinical experts. It is subsequently presented to our expert committee for appraisal against matters of policy and other considerations in light of new evidence.
Consultations will be available to view for a period of 2 weeks; replies must be received before midnight on the closing date specified in the draft content.
To receive alerts about content for consultation, sign up to the BNF Newsletter.
Current consultations for BNF
There are currently no open consultations for BNF.
Current consultations for BNF for Children
There are currently no open consultations for BNF for Children.
How to get involved
1. Read the draft BNF Publications content
2. Read the Guidance for reviewers document
3. Use the Consultation response document to create your consultation response
Return your consultation response document (including supporting evidence) by the closing date specified in the draft content.
Consultation comments
After an open consultation, BNF responses to individual comments and/or common themes received will be available to view for a period of 2 weeks once final BNF Publications content has been published.
There are currently no consultation comments to view.
Sign up for the BNF monthly newsletter
Sign up to receive the latest information about BNF consultations and updates.
Create your own customised formulary
Powered by BNF, FormularyComplete allows you to create your own customised formulary, supporting you locally to make quick, clinically informed decisions.
Access BNF content online, on the move and in print
BNF and BNF for Children are available online through MedicinesComplete.
The essential app for iOS and Android to access medicines information on-the-go.
Essential reference books published in updated book form twice a year.
BNF content is available for licensing through Pharmaceutical Press.